enGene Holdings Inc
NASDAQ:ENGN
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
S
|
Solwers Oyj
OMXH:SOLWERS
|
FI |
enGene Holdings Inc
Total Current Assets
enGene Holdings Inc
Total Current Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Current Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
e
|
enGene Holdings Inc
NASDAQ:ENGN
|
Total Current Assets
$201.4m
|
CAGR 3-Years
107%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
B
|
Bright Minds Biosciences Inc
CNSX:DRUG
|
Total Current Assets
CA$84.3m
|
CAGR 3-Years
61%
|
CAGR 5-Years
149%
|
CAGR 10-Years
N/A
|
|
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
|
Total Current Assets
$492m
|
CAGR 3-Years
4%
|
CAGR 5-Years
3%
|
CAGR 10-Years
40%
|
|
|
X
|
Xenon Pharmaceuticals Inc
NASDAQ:XENE
|
Total Current Assets
$560.6m
|
CAGR 3-Years
-2%
|
CAGR 5-Years
25%
|
CAGR 10-Years
25%
|
|
|
Eupraxia Pharmaceuticals Inc
TSX:EPRX
|
Total Current Assets
CA$85.1m
|
CAGR 3-Years
50%
|
CAGR 5-Years
137%
|
CAGR 10-Years
N/A
|
|
|
Spectral Medical Inc
TSX:EDT
|
Total Current Assets
CA$5.3m
|
CAGR 3-Years
-19%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
-3%
|
|
enGene Holdings Inc
Glance View
enGene Holdings Inc is a CA-based company operating in Biotechnology industry. The company is headquartered in Saint-Laurent, Quebec and currently employs 2 full-time employees. The company went IPO on 2021-12-10. enGene Holdings Inc. is a holding company. The Company, through its subsidiary, enGene Inc., is engaged in developing non-viral gene therapies based on localized delivery of nucleic acid payloads to mucosal tissues. The Company’s proprietary dually derived chitosan (DDX) platform has a high degree of payload flexibility, including DNA and various forms of RNA with broad tissue and disease application. In preclinical animal and in vitro models, the Company’s DDX technology has been demonstrated to effectively induce expression of therapeutic genes following delivery to the lung, gastrointestinal tract, and urinary tract, and its lead product detalimogene voraplasmid (EG-70) is being developed for the treatment of bacillus calmette-guerin (BCG)-resistant non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS). EG-70 is a novel non-viral gene therapy designed to elicit a local immune response following the delivery to the bladder urothelium.
See Also
What is enGene Holdings Inc's Total Current Assets?
Total Current Assets
201.4m
USD
Based on the financial report for Oct 31, 2025, enGene Holdings Inc's Total Current Assets amounts to 201.4m USD.
What is enGene Holdings Inc's Total Current Assets growth rate?
Total Current Assets CAGR 3Y
107%
Over the last year, the Total Current Assets growth was -19%. The average annual Total Current Assets growth rates for enGene Holdings Inc have been 107% over the past three years .
